1、Next generation oxazolidinone antibiotic designed and developed by MicuRx
2、Target multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus,vancomycin-resistant Enterococci, penicillin-resistant Streptococcus pneumoniae, etc
3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 11th, 12th, 13th five-year period

• Patent filled in 2008
• China IND approved in 2010
• QIDP and Fast Track granted by US FDA by 2018
• China Phase 3 trial completed in 2019
• NDA granted priority review by NMPA in 2020
• NDA approved by NMPA in 2021

1、Injectable new oxazolidinone antibiotics designed and developed by MicuRx
2、Target multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus,vancomycin-resistant Enterococci, penicillin-resistant Streptococcus pneumoniae, etc
3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 13th five-year period

• Patent filled in 2015
• US Phase 1 trial completed in 2017
• QIDP and Fast Track granted by US FDA by 2018
• US Phase 2 trial completed in 2019
• China Phase 1 trial completed in 2021

1、Next generation polymyxin antibiotic designed and developed by MicuRx
2、Target multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Klebsiella pneumoniae, etc
3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 13th five-year period

• Patent filled in 2015
• US IND approved in 2020

1、Novel boron compound designed and developed by MicuRx
2、Target multidrug resistant Gram-negative bacteria

1、Novel pleuromutilin inhibitors designed and developed by MicuRx
2、Target multidrug resistant Gram-positive bacteria

1、Novel kidney-targeted treatment designed and developed by MicuRx
2、To achieve superior efficacy and safety by increasing the local concentration of drug via renal-targeted delivery

1、Novel kidney-targeted treatment designed and developed by MicuRx
2、To achieve superior efficacy and safety by increasing the local concentration of active drug via renal-targeted delivery

3CL protease of SARS-COV-2 was chosen as the target for developing oral small molecule inhibitor to treat COVID-19. Based on MicuRx's experience and expertise on new drug design and discovery, we are optimizing the structure of reported inhibitors, to improve oral bioavailability as well as efficacy. The project is at lead optimization stage.